<DOC>
	<DOCNO>NCT02733458</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety gemcitabine , etoposide , pegaspargase dexamethasone ( GELAD ) chemotherapy sandwich radiotherapy first-line treatment patient de novo stage IE/IIE extranodal natural killer/T-cell lymphoma , nasal type .</brief_summary>
	<brief_title>GELAD Chemotherapy Sandwiched Radiotherapy Treatment Stage IE/IIE Natural Killer/T-cell Lymphoma</brief_title>
	<detailed_description>Extranodal natural killer/T-cell lymphoma ( ENKTCL ) , nasal type , rare subtype non-Hodgkin lymphoma ( NHL ) relatively high incidence China . Radiotherapy alone stage IE/IIE diseases good response rate high relapse rate , range 20-50 % . The combination chemotherapy radiotherapy improve long-term survival patient stage IE/IIE disease . But optimal treatment schedule establish . This study design two cycle GELAD chemotherapy , follow 50-56Gy radiotherapy , complete additional two cycle GELAD chemotherapy . The efficacy safety sandwich chemoradiotherapy treatment stage IE/IIE ENKTCL measure .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>Pathological diagnosis extranodal natural killer/Tcell lymphoma , nasal type , previously untreated Eastern Cooperative Oncology Group ( ECOG ) performance status 0~3 Stage IE IIE disease least one measurable lesion nasal cavity , paranasal sinus , orbit , pharynx , Waldeyer 's ring , oral cavity . Preserved organ function : absolute neutrophil counter ( ANC ) &gt; 1.0×109/L , Platelet &gt; 50×109/L , hemoglobin &gt; 80g/L , total bilirubin ( TBIL ) &lt; 2×ULN , alanine transaminase ( ALT ) &lt; 2×ULN , serum creatinine＜1.5×ULN，fibrinogen≥1.0g/L , LVEF≥50 % No history chemotherapy radiotherapy . Signed Informed consent Concurrent cancer need surgery chemotherapy within 6 month . Significant complication : LVEF≤50 % , coagulopathy , autoimmune disease , severe infection , liver cirrhosis , hemophagocytic lymphohistiocytosis . Mental disorder . Pregnant lactation HIV , hepatitis virus C ( HCV ) , active hepatitis virus B ( HBV ) infection HBV DNA≥105 copies/ml . History pancreatitis Known history grade 3/4 allergy drug chemotherapy regimen . Enrolled trial treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>